NCT01302132已完成1 期
An Open Label Study to Evaluate the Pharmacokinetics of ASP1941 After a Single Oral Dose of 14C-labeled ASP1941 in Healthy Male Subjects
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Pharmacokinetics of ASP1941 to evaluate metabolism and excretion
研究概览
简要总结
This study investigates the pharmacokinetics, in particular the routes and extent of metabolism and excretion, of ASP1941 after a single oral dose.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Body weight between 60-100kg, BMI between 18.5-30 kg/m2, inclusive
排除标准
- •Pulse <40 or >90 bpm; Systolic Blood Pressure > 140 mmHg; Diastolic Blood Pressure >90 mmHg
结局指标
主要结局
Pharmacokinetics of ASP1941 to evaluate metabolism and excretion
时间窗: up to 216 hours
次要结局
- Identification of metabolic profile of ASP1941(up to 216 hours)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic FunctionHepatic ImpairmentNCT01863784Janssen Research & Development, LLC28
已完成
1 期
A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance HemodialysisEnd-Stage Renal DiseaseNCT02289703Janssen Research & Development, LLC16
进行中（未招募）
1 期
A clinical trial to find out how much tapentadol is in the blood of children who take tapentadol every 4 hours to treat short-term paiEUCTR2019-000205-77-PLGrünenthal GmbH15
尚未招募
不适用
PK of intra-vaginal oxybutyniNL-OMON20539iGalli BV8
已完成
1 期
A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic ImpairmentHepatic ImpairmentNCT01767948Janssen Research & Development, LLC30